Granules India Poised for Strong Future in Pharma R&D, Says Executive Director Priyanka Chigurupati.

Buoyed by consistent financial strength, Granules India is embarking on an aggressive strategic expansion, prioritizing a shift towards high-margin products and a deeper dive into non-legacy molecules. The ₹4,500 crore pharmaceutical company is also significantly boosting its production capabilities, according to Executive Director Priyanka Chigurupati.

In a recent discussion with businessline, Chigurupati outlined the company's roadmap, emphasizing its commitment to enhancing its product mix. This strategic pivot aims to not only optimize profitability but also to solidify Granules India's position as a key player in the evolving pharmaceutical landscape.

"Our steady financial performance in recent years provides a strong foundation for these ambitious initiatives," Chigurupati stated. "We are keenly focused on expanding our portfolio with offerings that yield higher margins, moving beyond traditional molecules to embrace more innovative and complex products."

The company's push into non-legacy molecules signals a clear intent to invest in research and development, aiming to capture new market segments and stay ahead of industry trends. This focus on a diversified and enriched product pipeline is expected to drive future growth and enhance shareholder value.

Furthermore, Granules India is actively working on augmenting its production capacity. This expansion is crucial to support the increased demand for its evolving product mix and to ensure the company can efficiently scale its operations to meet market needs.

Chigurupati also shared insights on the broader pharmaceutical industry, highlighting the dynamic environment and the increasing importance of innovation and strategic differentiation. Granules India's current initiatives appear well-aligned with these industry trends, positioning the company for continued success in the coming years.